Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

ASTRAZENECA PLC (AZN)

79
Delayed Quote. Delayed London Stock Exchange - 10/24 11:35:17 am
4327.5 GBp   -0.16%
1d ago Ex-Bank of New York Mellon employee pleads guilty to insider trading
1d agoDJPfizer Results Will Play Second Fiddle to Dealmaking Outlook -- Earnings..
1d agoDJFlu-Shot Supply Dented by Production Woes
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

UK Health Watchdog Backs Lung Cancer Drug From Roche

05/09/2012 | 07:16pm US/Eastern

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
Latest news on ASTRAZENECA PLC
6h ago ASTRAZENECA : Drug boost for cervical cancer fight
1d ago Ex-Bank of New York Mellon employee pleads guilty to insider trading
1d agoDJPfizer Results Will Play Second Fiddle to Dealmaking Outlook -- Earnings Prev..
1d agoDJFlu-Shot Supply Dented by Production Woes
1d ago ASTRAZENECA : Lilly Reports Third-Quarter 2014 Results
1d agoDJFlu-Shot Supply Dented by Production Woes
1d ago FTSE falls, posts strongest week since August
1d ago AstraZeneca cancer drug pipeline gets boost from European green light
1d ago ASTRAZENECA : Gets EMA Marketing Approval For Lynparza (UPDATE)
1d ago ASTRAZENECA : Gets EMA Marketing Approval For Lynparza Cancer Treatment
Advertisement
Chart
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF